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A Review on Comb Shaped Amphiphilic Polymers for 
hydrophobic drug solubilisation 
 
Abstract 
Comb shaped amphiphilic polymers are rapidly emerging as an alternative approach 
to amphiphilic block copolymers for hydrophobic drug solubilisation. These polymers 
consist of a homopolymer or copolymer backbone to which hydrophobic and 
hydrophilic pendant groups can be grafted resulting in a comb like architecture. The 
hydrophobic pendants may consist of homopolymers, copolymers or other small 
molecular weight hydrophobic structures. In this review, we focus on hydrophobically 
modified pre-formed homopolymers. Comb shaped amphiphilic polymers possess 
reduced CAC values compared to traditional surfactant micelles indicating increased 
stability with decreased disruption experienced on dilution. They have been fabricated 
with diverse architectures and multifunctional properties such as site specific targeting 
and external stimuli responsive nature. The application of comb shaped amphiphilic 
polymers is expanding; here we report on the progress achieved so far in hydrophobic 
drug solubilisation for both intravenous and oral delivery. 
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1.0 Introduction 
Amphiphilic polymers were first reported in 1984 to form nano-sized polymeric self-
assemblies and was indicated to exhibit the potential as hydrophobic drug solubilisers 
[1]. Since the beginning of 1990s, extensive research has been conducted to explore 
the ability of these amphiphilic polymers to encapsulate hydrophobic drugs in 
particular for intravenous administration [2-6]. Today, a plethora of amphiphilic 
polymers have been designed such as block copolymers [7], comb shaped polymers 
[8], star shaped [9] or dendrimers [10] (Fig. 1) albeit all share the common polymer 
architecture consisting of both hydrophobic and hydrophilic segments within the same 
macromolecule [6]. Among these amphiphilic polymers, the most common type is 
block copolymers and they have been extensively reviewed [11-15]. Therefore, in this 
article, we focus on comb shaped polymers, the second most common type 
amphiphilic polymers. The polymer architecture of the comb shaped polymers, the 
physical-chemical properties of comb shaped polymers and their use in oral and 
intravenous delivery will be evaluated in this review. 
 
2.0 Comb Shaped Amphiphilic  Polymer 
The interest in using comb shaped amphiphilic polymers for drug delivery was 
reported in mid 1990s where Chiu and colleagues first described the fabrication of an 
amphiphilic graft polymer comprising of stearyl methacrylate, methyl acrylate, acrylic 
acid and acrylate derivative of polyethylene glycol (PEG) monomer units [16]. This 
copolymer consists of hydrophobic (primarily stearyl groups) and hydrophilic (PEG 
part) side chains together with anionic carboxylate groups. Polymeric micelles with 
two size populations of 50nm and 389nm were formed in aqueous environments 
capable of encapsulating pyrene, a model hydrophobic compound. The authors 
attributed the different size population phenomenon was due to loose aggregates / 
large association complexes were in dynamic equilibrium with smaller more compact 
micelles in water [16]. Today, comb shaped polymers can be made up of either a 
water soluble homopolymer or copolymer backbone with hydrophobic pendant groups 
conjugated or „grafted‟ onto the backbone forming a comb shaped structure (Fig. 1B) 
[8,17,18]. The hydrophobic pendants may consist of homopolymers [19], copolymers 
[20] or other small molecular weight hydrophobic structures [21]. Often, hydrophilic 
groups such as quaternary ammonium moieties [22] or polymer such as polyethylene 
glycol (PEG) [23] are added to improve water solubility. Due to the diverse structure 
of amphiphilic graft polymers, in this review, we only focus on hydrophobically 
modified pre-formed homopolymer backbone. In aqueous solution, spontaneous nano 
aggregates are formed upon aggregation of the hydrophobic pendant groups. As a 
result, a hydrophobic core is formed and stabilised by the water soluble polymer 
backbone [24,25,26]. Comb shaped amphiphilic polymer can form polymeric micelles 
[17], nanoparticles [19], disc-like structures [27] and vesicles [28] in the aqueous 
environments. Adjusting the structural components such as the hydrophobic pendant 
group or the level of grafting has a direct impact on the physical properties of the self-
assemblies formed [8,17,21,29]. Comb shaped polymers have previously been 
reported to successfully encapsulate hydrophobic drugs such as Cyclosporine A 
[8,19], doxorubicin [30] and paclitaxel [31,32] and other agents for other therapeutic 
agents such as proteins [8], peptides [33] and genes [32,34].  
 
3.0 Types of water soluble pre-formed polymer backbones  
 
3.1 Carbohydrate polymers 
Carbohydrate polymers such as chitosan [22,35], dextran [36] (Fig. 2E) and 
hydroxypropylmethyl cellulose [37] have been widely used as polymer backbones for 
comb shaped amphiphilic polymers (Table 1). Prabaharan synthesised 
carboxymethylchitosan-g-phosphatidylethanol amine, CMC-PEA using chitosan as 
the backbone [38]. Chitosan (Fig. 2D) is known for its non toxic, biodegradable and 
biocompatible nature. By grafting PEA hydrophobic pendant groups via the primary 
amine groups on the chitosan homopolymer backbone spontaneous self-assemblies 
were formed in aqueous environment where lipophilic drug, ketoprofen was 
encapsulated inside the hydrophobic core [38]. Yu et al. grafted chitosan (Chi) with 
biodegradable polyester poly(caprolactone) (PCL) forming PCL-g-Chi 40-60nm nano 
aggregates [39]. They reported that the physical properties of self-assemblies could be 
tailored by controlling the level of PCL grafting onto the chitosan backbone. The 
biodegradability of PCL-g-Chi makes it an ideal delivery system and further work is 
currently underway to investigate the potential of PCL-g-Chi as a drug solubilising 
agent [39]. Other biodegradable amphiphilic chitosan derivatives have been reported 
including chitooligosaccharide-graft-poly(ε-caprolactone) (COS-g-PCL) [40], 
chitosan-graft-poly(ethylenimine)-graft-poly(ethylene oxide) (chitosan-g-PEI-PEG-
OH) [41] and hexanoyl chitosan-graft-poly(ethylene glycol) (PEG-g-hexanol 
chitosan) [42]. 
 
Like chitosan, dextran is a polysaccharide renowned for its attractive qualities such as 
biocompatibility [43], biodegradability [44] and versatility [45]. Francis and 
colleagues grafted dextran with a series of poly(ethyleneglycol) alkyl ether  forming 
(DEX-g-PEG-C) [46]. The dextran derivatives were investigated for their ability to 
form polymeric micelles in aqueous environments. The results showed that CAC 
decreased with higher PEG-Cn units per dextran chain and also with decreased 
molecular weight of dextran [46]. Amphiphilic dextran derivatives have been 
extensively reported for use as drug solubilising agents (including Cyclosporin A and 
Paclitaxel) [36,43-48]. Recently modified dextrans with poly(N-isopropylacrylamide) 
pendant groups have been reported possessing more sophisticated aggregates with 
stimuli responsive functionalities (pH or temperature) [49,50].  
 
3.2 Synthetic polycations polymers 
Most of the synthetic polycations (Table 1) such as polyethylenimine (PEI) [51,52] 
(Fig. 2A), poly-L-lysine (PLL) [42] (Fig. 2B) or polyallylamine (PAA) [53] (Fig. 2C) 
were first used as gene delivery systems due to the presence of amine functional 
groups for complexation with negatively charged DNA. PEI is known for its 
abundance of primary amines on the polymer backbone which provide extensive 
possibilities for grafting and further functionalisation [54-56]. PEI was discovered 
long before Bousiff et al. but these authors were first to introduce it as a non-viral 
vector for gene delivery [57]. However, due to the inherent cytotoxicity of PEI, 
attempts have been employed to improve the biocompatibility profile as well 
enhancing its efficiency as gene delivery system. One of the methods used is adding 
hydrophobic groups such as cholesteryl [52], hydrocarbon chains such as palmitoyl 
[51], cetyl [8], or polymer such as poly(caprolactone) [51].  Most of the research 
showed that grafting of hydrophobic moieties onto PEI improves the safety profile of 
PEI [8,58,59], which was attributed to the reduction of primary amines after 
hydrophobic conjugation [58,59]. In recent years, hydrophobically modified PEIs 
have been used for oral delivery of hydrophobic drugs such as cyclosporine A [8] or 
for targeting both hydrophobic drugs and gene to cancer cells [60]. 
Wang and colleagues substituted PLL with hydrophobic palmitoyl groups to form 
PLL amphiphiles [28]. They showed that addition of cholesterol is needed to form 
vesicles upon sonication in aqueous solution [28]. Recently, we reported on the use of 
polyallylamine (PAA) amphiphiles for hydrophobic drug solubilisation [21,61,62].  
Previously PAA has been used clinically as an oral phosphate sequester [63], 
indicating a good degree of biocompatibility. PAA also possesses a high degree of 
primary amines making them amenable to simple modifications. The different types 
of hydrophobic pendant groups grafted onto PAA normally have an impact on the 
type of self-assemblies formed in aqueous solution [21].  
 
3.3 Different pendant groups grafted to homopolymer 
The hydrophobic pendant groups grafted onto the homopolymer backbone of comb 
shaped polymers are usually alkyl chains [17,51,64], acyl groups [65,66] or 
cholesterol moieties [17,21,62,67,68] (Fig. 3).  
Wang grafted hydrophobic linear cetyl chains (Fig. 3A) onto a poly(ethylenimine) 
(PEI) backbone [69]. Interestingly it was reported that at low molar cetyl grafting 
(<23%) spontaneous aggregation in aqueous media formed micellar structures. At 
higher levels of cetyl grafting (23-42%) vesicle formation occurred, this phenomenon 
was also observed upon addition of hydrophobic cholesterol into the solution at lower 
grafting levels of 3-43% [69]. On further increasing the degree of cetylation (≥ 49 %) 
dense nanoparticles are formed. These results indicated that at varied levels of 
hydrophobicity these amphiphilic polymers resulted in a range of colloidal structures 
[58]. These findings have been observed across a large number of studies on different 
polymer amphiphiles [8,17,28,70].   
Cholesterol (Fig. 3C) is a commonly occurring sterol in the body [71]. It regulates 
membrane fluidity and plays an important role in spontaneous association of 
molecules in biological pathways [86]. Yusa and colleagues reported the graft 
polymerization of sodium 2-(acrylamido)-2-methylpropanesulfonate with cholesteryl 
methacrylate (CholMA) and cholesteryl 6-methacryloyloxyhexanoate (Chol-C5-MA) 
[72]. Even at low cholesterol grafting ratios, those polymers still possessed a strong 
tendency to form aggregates [72].  This phenomenon was also observed by Thompson 
on grafting cholesterol onto a PAA backbone where 2.5%-5% mole modification 
resulted in formation of nano-aggregates [17]. Unlike alkyl chains, it is thought that 
high number of carbon atoms in cholesteryl moieties may result in the observed 
phenomenon. Xu and colleagues also reported that the use of cholesterol as a 
hydrophobic cap on poly(2-methacryloyloxyethyl phosphorylcholine) improving the 
cytotoxicity [72]. Interestingly, when cholesterol is added into self-assemblies formed 
by amphiphilic graft polymers, very often it inserts into the  forming bilayer vesicular 
structures [17,28,69], giving rise to the potential application of incorporating 
hydrophilic drug in the aqueous core. 
 
Previously, fluorescent tags such as rhodamine [17,73] and fluorescein isothiocynate 
(FITC) [74-76] were conjugated onto amphiphilic polymers for in vitro and in vivo 
visualisation [17,73]. However, these dyes could affect the physical and chemical 
properties of the nano aggregates and hence altering the tissue interactions and 
cytotoxicity [77]. As such, amphiphilic polymers modified with aromatic fluorophores 
(e.g. pyrene, naphthalene, dansyl) have been developed (Fig. 4) [78]. Apart from 
simultaneous formation of nano-aggregation in aqueous solution for hydrophobic drug 
solubilisation [19], these polymers have a range of potential applications including in 
vivo tracers, fluorescent probes and cell labelling to mention a few [78]. 
 
Hydrophobic drug molecules can also be used as pendant groups in amphiphilic graft 
polymers [79-85]. Fan and colleagues created disulfide linked poly(amino amine) 
structure using methyl ether PEG (mPEG-g-SSPAA) [79]. To this compound 
antitumor agent camptothecin was covalently conjugated as a secondary pendant 
group via hydrolysable bonds. Conjugation of camptothecin to the polymer backbone 
increased its aqueous solubility and stability. Upon incubation with mouse muscular 
cells (L929), the polymer-drug conjugate exhibited reduced cytotoxic effect on the 
cells compared to the free drug which was thought to be due to the controlled release 
of camptothecin from the micelle [79]. 
 
3.4 Types of hydrophilic moieties 
Hydrophilic moieties including poly(ethylene glycol) (PEG) [23,83,84] and 
quaternary ammonium ions [17,22,85,86] are commonly attached to the homopolymer 
backbone (Fig. 5). PEG moieties improve the safety profile of the delivery system and 
can provide the nano aggregates with „stealth‟ properties in vivo resulting in reduced 
phagocytotic clearance leading to increased drug circulation times [22,87,88]. In 2000 
Brown and colleagues found that attachment of mPEG to their palmitoyl-PLL comb 
shaped amphiphiles reduced the surface charge, resulting in a neutral zeta potential 
leading to reduced cytotoxic effect on 4549 and A351 cell lines [89]. These results are 
consistent with the theory that addition of PEG both increases stability and decreases 
cytotoxicity of amphiphilic graft polymers [23,83,84,90,91]. 
 
Thompson and colleagues reported that addition of the quaternary ammonium ion 
onto PAA amphiphiles increased their aqueous solubility whilst reducing the size of 
their corresponding self-assemblies [17]. They also reported that hydrophilic 
substitution reduced the in vitro cytotoxic effect of the amphiphiles on human 
colorectal carcinoma (Caco-2 cells) [70,79,92]. It is thought permanently charged 
amines (i.e. quaternary ion) are less cytotoxic than protonable amines [92] and are in 
agreement with Uchegbu and colleagues findings [24]. Table 1 shows the 
homopolymer backbones together with the hydrophobic and hydrophilic pendant 
constituents of some common graft amphiphilic polymers.  
 
4.0 Comb Shaped amphiphilic polymer for site specific delivery 
The versatility of the comb shaped amphiphilic polymers has enabled the design of 
stimuli responsive polymers which respond to external triggers such as temperature or 
pH [38,93-95] (Fig. 6). Prabaharan and colleagues fabricated a pH responsive 
chitosan derivative graft polymer of carboxymethyl chitosan-graft-
phosphatidylethanolamine (CMC-g-PEA). The CMC-g-PEA possessed a pH-
dependent swelling behaviour, which resulted in elevated levels of drug release. At 
physiological pH (7.4) 80% of ketoprofen release was observed after 70 h, however 
this was significantly decreased in acidic pH‟s (pH 1.4) where 80% drug loss was 
experienced after only 45 h [38]. Gu and colleagues synthesized a novel pH 
responsive poly(L-lysine) grafted with cholic acid and subsequently PEGylated via a 
benzoic imine linker (PEG-PLL-CA) [96]. This system was stable at physiological pH 
(7.4) but at lower pH values representative of endosomal conditions (pH 5.4) the 
benzoic imine linker degraded resulting in the release of the „stealth‟ PEG, leaving the 
PLL-CA micelle which possessed much higher zeta potential values. Upon a decrease 
in the pH from 7.4 to 5.4 the zeta potential of PEG14-PLL-CA50 micelles raised from 
0 to 36 mV. This increase in zeta potential resulted in a membrane disruptive property 
in porcine red blood cells. They concluded that this membrane disruptive behaviour at 
a pH lower than the extracellular pH of cells, can potentially be useful as a delivery 
system for intracellular transport into solid tumours [96].  
 
Shi and Zhang synthesised an amphiphilic dextran derivative via conjugation of 
biocompatible and thermoresponsive poly(N-vinyl caprolactam) (PNVCL) pendant 
groups [97]. PNVCL is known to possess a lower critical solution temperature 
(LCST) at 32°C in aqueous solutions [97]. At temperatures above the LCST values 
spontaneous phase separation or precipitation occurs, this results in transition of the 
polymer solution from a well-dissolved coil structure to a less-soluble globular state 
and hence leading to drug release. Upon conjugation with the dextran backbone, Shi 
and Zhang showed that the new amphiphile also possessed an inherent 
thermoresponsive nature [97]. They showed that a temperature-dependent 
transmittance change occurred when PNVCL was grafted onto dextran with a LCST 
value of 31.9 °C. This value decreased from 35.4°C to 31.9°C upon dilution of the 
polymer from 0.87 g/L to 0.10 g/L respectively [97].  
 
Similar to block-copolymer, ligands such as folate [98-100] galactose [101, 102] or 
antibodies [103] have been grafted onto comb shaped amphiphilic polymers. Folate 
receptors are commonly used for actively targeting cancerous tumour sites 
[98,100,103,104]. Morris and Sharma recently fabricated a site specific delivery 
system based on PEI amphiphiles for gene delivery [103]. The graft polymer consists 
of arginine modified oligo(alkylaminosiloxane) (P(SiDAAr)5) grafted onto a PEI 
backbone with poly(ethylene glycol)-folic acid (PEG-FA) conjugated forming 
P(SiDAAr)5FP2 [103]. Since folic acid is necessary for healthy proliferating cells, 
rapidly dividing cancerous cells experience and increased „appetite‟ for such 
compound and hence over express folate receptors [104]. Morris and Sharma 
incubated their nanoparticulates with the ubiquitous keratin-forming tumor cell line 
HeLa (KB) cells, known for their high levels of folate receptors. They observed an 
increase in cellular uptake of the P(SiDAAr)5FP2 compared to the P(SiDAAr)5 and 
PEI alone. This enhanced transfection indicating P(SiDAAr)5FP2 as potential future 
for gene therapy [103]. 
 
Table 1. 
 
5.0 Micelle formation, drug loading and physicochemical properties 
5.1 Critical Aggregation Concentration (CAC) 
The lowest concentration required for polymeric aggregates to form in aqueous 
environments is known as the critical aggregation concentration (CAC). In general 
comb shaped amphiphiles have a higher CAC value than block copolymers which can 
be seen in Table 2. This can be attributed to the intramolecular aggregation 
mechanism by which they can spontaneously assemble forming looser larger 
aggregates [19].  
 
Table 2.  
 
Essa and colleagues synthesised a series of PEG modified poly(D-Lactide) (PLA) 
graft (PL-g-PEG) and multiblock copolymers (PLA-PEG-PEL) [126]. Their findings 
showed that when PEG was grafted onto the PLA backbone the polymer showed 
different physicochemical properties than when PEG was copolymerized to PLA. In 
graft polymer an increase in immiscibility was observed in solution, whereby more 
PEG moieties „separated‟ from the hydrophobic PLA reaching the surface of the 
nanoparticles. This phenomenon resulted in a greater degree of hydrophobicity inside 
the nanoparticles core when compared to the copolymerised counterpart [126]. This 
implies that graft or comb shaped polymers form more well defined aggregates, 
perhaps giving rise to greater drug encapsulation abilities [126]. 
It is well documented that at lower CAC values amphiphilic polymers experience 
increased stability resulting in less disruption upon dilution in vivo [2,3,4] (Fig. 7).  
There are generally 4 parameters affecting the CAC for amphiphilic graft polymers: a) 
the level of hydrophobic chain grafting [8,17,21] b) the length of hydrophobic 
pendant groups [17] c) the type of hydrophobic pendant groups [21] d) the molecular 
weight of the polymer backbone [28].  
 
The major driving force behind polymeric self-assembly is the decrease in Gibbs free 
energy which results from the hydrophobic pendants being removed from the aqueous 
environment into the hydrophobic core as the nano aggregate forms [6]. Most of the 
studies to date has shown that higher levels of hydrophobic grafting results in lower 
CAC for amphiphilic graft polymers [8,17,21]. Thompson et al. reported that PAA 
amphiphiles with increased molar modification of hydrophobic pendant group 
possessed lower CAC values irrespective of the type of pendant group [17]. He also 
showed that cholesterol PAA amphiphiles (Ch) possessed lower CAC values 
compared with palmitoyl and cetyl chains due to the increased alkyl chain length in 
the cholesterol moiety. This resulted in greater hydrophobic interactions [17]. The 
stereochemistry of the hydrophobic pendant group also has a direct impact on the 
CAC value [8,21,70]. Recently we reported the fabrication of PAA amphiphiles with  
hydrophobic aromatic pendant groups [21].  Interestingly from that work we observed 
that PAA amphiphiles modified with both fmoc and naphthalene moieties possessed 
two CAC values [21]. It is proposed that the planar structure of the aromatic groups 
resulted in stacking at higher concentrations initiating excimer formation [21]. The 
CAC values obtained from our PAA amphiphiles were larger than normally achieved 
using graft polymers, perhaps due to the aromatic rings exhibiting a lower degree of 
hydrophobicity or due to the aromatic groups being in closer proximity to the water 
molecules forming looser aggregates [26,68]. In 2006, Cheng and colleagues reported 
conjugation of alkyl chains onto poly(ethylenimine) (PEI) backbones of different 
molecular weight [8]. It was shown that by keeping the % molar grafting ratio 
constant between cetyl chains (5 % molar ratio) and  PEI monomer unit, resulted in 
similar CAC values obtained across PEI with molecular weight of 1.8, 10 and 25 KDa  
[8,69].   
 
5.2 Drug loading process 
Two methods are traditionally used to incorporate hydrophobic drugs inside 
polymeric micelles formed by amphiphilic block copolymers or graft polymers 
[12,127-129] (Fig. 8A&B). The first method is solvent evaporation, where polymer 
and drug are dissolved in organic solvents [127,128]. After removal of the solvents 
under reduced pressure, the residue is reconstituted with water and spontaneous 
aggregation is initiated [127]. In the second method, dialysis is used where the 
polymer and drug are dissolved in water and miscible organic solvents. The solution 
is placed inside a dialysis membrane followed by exhaustive dialysis against water 
[12,129]. The exchange of solvent and water molecules in the dialysis bag drives the 
formation of self-assemblies with encapsulated drug [129]. Excess free drug is then 
filtered out of solution using a 0.45 micron syringe filter [129]. In this case the nano 
aggregates exceeded the pore size of the membrane and remained inside the dialysis 
tubing. However, the use of organic solvents might not be favourable due to the 
possibility of residual organic solvents, which could be harmful upon administration 
in vivo [130]. 
 
Recently, a quick and simple technique has been adopted for loading hydrophobic 
drug into self-assemblies formed by graft polymers [8,17,21]. Probe sonication of the 
polymeric amphiphiles in aqueous solution encourages aggregation formation [8] 
(Fig. 8C). Hydrophobic drug is then added into the polymeric self-assemblies and 
upon sonication, the drug is encapsulated within the hydrophobic core of the self-
assemblies [61].  Excess drug is then filtered via syringe filtration. The absence of 
organic solvents in this method eliminates the safety issue concerns associated with 
the aforementioned methods. 
 
5.3 Factors affecting drug loading in polymeric self assemblies 
The driving force for hydrophobic drug solubilisation inside polymeric self-
assemblies is associated to basic energetic principle [2]. As the amphiphilic polymers 
spontaneously form their unique core–shell supramolecular structures in aqueous 
solution, the lipophilic drug molecules accumulate within the hydrophobic core. 
These molecules remain physically entrapped inside the core with the self-assemblies 
continuously and spontaneously disrupting and reforming in dynamic equilibrium. 
This phemonenon is only observed at concentrations above their CAC values 
[6,131,132]. A good polymeric solubiliser should have favourable and stronger 
interactions with solubilisate than the intermolecular interactions among the 
solubilisate molecules [133]. This is especially important for those solubilisates with 
high levels of crystalline structures [134,135]. A number of research groups have 
looked at the parameters affecting the drug solubilisation capacity of amphiphilic 
block copolymers. The factors affecting the drug loading can be a) the ratio of 
hydrophobic block versus the hydrophilic blocks [136, 137], b) drug loading 
concentration [109] c) compatibility between the hydrophobic block with the drug 
[11,138]  d) drug physicochemical properties [139]  e) the glass transition temperature 
of the hydrophobic polymer segment [139]. In recent years a few experimental works 
have shown that attachment of drug molecules or functional groups with similar 
chemical structure of drugs onto the polymers could enhance the drug-polymer 
interaction [138,139,140]. For example, Mahmud and colleagues conjugated 
doxorubicin (DOX) to the hydrophobic block of poly(ethylene oxide)-blockpoly(ε-
caprolactone) (PEO-b-PCL) which favoured DOX solubilisation [141],while the 
inclusion of cholesteryl groups in the PEO-b-PCL also resulted in a higher 
solubilisation of cucurbitacin I, a cholesterol drug, than the parent polymer [142]. 
 
Unlike those block copolymer micelles [141,142] the pendant group attached on a 
pre-formed water soluble polymer is the only hydrophobic moiety that will form the 
hydrophobic microdomains and contribute to the major interaction with the 
hydrophobic drug molecules. To date there are limited studies on the interaction 
between the hydrophobic drugs and the comb shaped polymers. We have conducted a 
number of systematic investigations on the impact of hydrophobic pendant groups of 
comb shaped amphiphilic polymers on the hydrophobic drug solubility enhancement. 
We have shown that poly-L-lysine (PLL) modified with sterol pendant groups 
(cholate) resulted in higher encapsulation of sterol drugs such as estradiol and 
prednisolone compared to PLL attached with alkyl chains such as palmitoyl pendant 
groups [143]. The structural compatibility between the drug molecules and 
hydrophobic pendant groups has resulted in better drug incorporation into the micellar 
structures [143].  As shown in Table 1, most of the hydrophobic pendant groups used 
in hydrophobically modified pre-formed water soluble polymers consist of 
hydrocarbon chains despite most hydrophobic drugs consist of aromatic or cyclic ring 
systems. Therefore, our research has also focussed on the attachment of aromatic 
groups to PAA, where the aromatic groups serve as the only hydrophobic moiety. We 
investigated the ability of novel PPA modified with different types and levels of 
aromatic pendant groups (Fluorenylmethoxy carbonyl (Fmoc) and dimethylamino-1-
naphthalenesulfonyl (Dansyl) (Fig. 9) on the enhancement of hydrophobic drug 
solubility of propofol, griseofulvin and prednisolone. Similar to studies on 
amphiphilic block copolymers, we have shown that increasing the level of 
hydrophobic modification would result in higher lipophilic content and thus causing 
stronger interaction with the drug molecules, which leads to higher drug encapsulation 
[144].  
 
Interestingly, comparison among the aromatic modified PAAs reveals the poor 
solubilising capacity of Fmoc compared to Dansyl, which we hypothesised was due to 
the excimer formation of Fmoc at higher polymer concentrations [61]. The flat 
stereochemistry of aromatic structures allow - stacking and hence forming 
excimers, a known phenomenon supported by others [145]. This limits the expansion 
of the core to accommodate more drugs at higher concentrations, which in contrast to 
the presence of the N,N-dimethylamino side chain in the Dansyl moiety. The side 
chain gives rise to a 3D structure, thus hindering any stacking interactions of the 
aromatic rings [21]. As a result, the self-assemblies are able to enlarge its core to 
accommodate a larger amount of drug molecules. Another observation was the comb 
shaped amphiphilic polymers seem to have a much higher loading capacity (LC) 
[54,61] (Dansyl grafted PAA exhibited LC > 100% [61]) compared to most of the 
reported block amphiphilic polymers, which is typically less than 20% [29,146-148].  
 
In addition to the type and level of hydrophobic pendant groups, the molecular weight 
of the polymer backbone also plays an important role in drug encapsulation. Various 
molecular weight of PEI ranging from 1.2KDa, 10kDa and 20kDa were cetylated and 
subsequently quaternised and their ability to encapsulate cyclosporine was 
determined. It was found that the 10kDa polymer showed the highest encapsulation 
[8]. Other contributing factors such as initial drug loading ratios also played an 
important role. Qui and Bae grafted cationic PEI with various molecular weights of 
poly(ε-caprolactone) (PCL) 1800-5500 KDa. They found that increasing doxorubicin 
initial feed ratios resulted in higher amount of solubilised doxorubicin (DOX) 
irrespective of different molecular weight of PCL [60]. They concluded that the 
presence of the hydrophobic drug inside the polymeric nano aggregate core increased 
its hydrophobicity. The stronger hydrophobic interactions results in greater driving 
force for drug solubilisation and hence a higher drug loading capacity was observed 
[60]. 
 
6.0 Comb Shaped Amphiphilic Polymers for Anticancer Therapeutics 
Polymeric self-assemblies have been extensively investigated for their ability to 
deliver anticancer agents to tumour sites [62,131,149-153]. Their unique size enables 
accumulation in tumour tissues due to the enhanced permeability and retention effect 
(EPR) [6,25,154-157]. Qui and Yan developed a graft amphiphilic polymer based on 
polyphosphazene derivatives for the delivery of DOX, an anticancer agent [30]. This 
was achieved by grafting hydrophobic ethyl tryptophan onto the polyphosphazene 
followed by the addition of hydrophilic PEG (Fig. 10). After the addition of DOX to 
the grafted amphiphile formed a core-shell structure with the drug incorporated inside 
the hydrophobic core. When they exposed their formulation to HeLa cells for 24 h 
they discovered that the loaded aggregates had a higher IC50 value (0.88 ugmL
-1
) 
when compared to the free DOX drug (0.22 ugmL
-1
). However, the nature of the 
polymeric nano aggregates is such that they control the release over a long period of 
time, hence after 48 and 72 h, the DOX-loaded micelles exhibited comparable 
cytotoxicity with that of free drug. In the in vitro release studies they showed that 
after 50 h, the drug had not yet been fully released from the polymer nano aggregates 
[30]. These results indicate that the PEG/EtTry-PPPs micelles have great potential as 
sustained release vehicles; however, in vivo studies are needed to confirm this theory.  
 
The synergistic effect whereby the presence of a cytotoxic drug inside a nontoxic 
carrier vehicle showing greater potency has been well documented using polymeric 
amphiphiles [158-161]. Westedt and colleagues reported such phenomenon when 
loading graft copolymer poly(vinyl alcohol)-g-poly(lactide-co-glycine) (PVA-g-
PLGA) with paclitaxel [162]. Westedt observed that by tailoring the composition of 
the PVA and PLGA it is possible to control the drug release kinetics for desired 
clinical application. The cytotoxic effect of the unloaded and loaded nano aggregates 
was determined; the unloaded aggregates showed no toxic effect on primary rabbit 
vascular smooth muscle cells (RbVSMC) up to 370 µgmL
-1
 [162]. However, when the 
formulation was exposed to the RbVSMC, the polymer loaded paclitaxel possessed up 
to a 2-fold decrease in IC50 (concentration at which 50% of cell viability was 
achieved) compared to the free drug [162]. This effect can be attributed to the 
polymer carrier vehicle not only protecting the drug but also, enabling the drug to 
enter the cell more efficiently [162-164].  
Temperature responsive (thermo responsive) and pH responsive polymeric 
amphiphiles hold great potential for cancer therapy. Cancerous tissue proliferates at 
an increased rate compared to healthy tissue and as such at higher temperature (40 – 
44 ºC) and a lower pH (<6.75) [165,166]. Thermo and pH responsive amphiphiles can 
be fabricated to release their payload upon slight change of temperature/pH making 
them ideal candidates as carrier vehicles for anti-cancer agents.  
Graft polymers based on poly(amine) backbones are commonly studied for cancer 
therapy [167-169]. Poly(amine) polymers are stable in aqueous solution at 
physiological pH. Polymeric aggregates composing of histidine pendant groups on 
poly(amino acid) backbone (PHEA-g-C18) possess inherent pH responsive nature 
[170]. Histidine is an endosomolytic compound causing rupture to endosomal 
membranes at lower pH (pH 5.4) [170,171] The release of DOX from the polymeric 
nano agregates has been shown to be accelerated at pH 5 due to swelling of the 
micellar structure [170]. Once the DOX is released from the endosome, it can diffuse 
into the nucleus to access its target resulting in a greater toxic effect when incubated 
with HeLa cells [170]. 
 
Poly(amine) graft amphiphiles have been created by grafting of poly(amino ester) 
with octadecyl acrylate forming PEA-g-ODA [168] (Fig. 11A). These polymeric nano 
structures achieved 35% DOX loading efficiency using the dialysis method. The 
increased potency on hepatoma (HepG2) cells shows potential as a therapeutic carrier 
vehicle. The polymer structure showed good buffering potential at physiological pH 
(7.4) with degradation occurring at lower pH‟s representative of intracellular 
environments (pH 5). At the lower pH  DOX release occurred indicating the potential 
of PEA-g-ODA as a controlled release drug carrier [168]. Poly(amide amine) was 
grafted with a methyl ether PEG pendant group (PAA-g-mPEG) (Fig. 11B) [169]. Sun 
and colleagues reported that the micelles produced, were „dis-assembled‟ in 
physiological environments and were less than 50nm. The self-assemblies were 
capable of loading 20%wt. DOX. HeLa and HepG2 cell lines were exposed to the 
formulation for 2 h, confocal microscopy was used to image the cells. Interestingly, 
the free DOX was only observed within the cell cytoplasm, however in the cells 
exposed to the DOX loaded PAA-g-mPEG, the DOX could be visualised within the 
cell nucleus. These result indicated that the polymeric nano carrier assisted in nuclear 
drug uptake [169].  
 
Chitosan derivatives have also been studied for their use as drug carriers for 
therapeutic agents [172-174]. SN-38 is an antitumoral agent (a more potent form of 
camptothecin: 7-ethyl-10-hydroxy-camptothecin) which has been effectively 
solubilised in the chitosan grafted with poly(captrolactone) (CS-g-PCL) hydrophobic 
core [121]. The drug encapsulation resulted in an increased aqueous solubility with 
encapsulation efficiency up to 84% (similar to block amphiphilic polymers consisting 
of poly-lactide-co-glycolide-b-polyethylene glycol-folate (PLGA-PEG-FOL) with 
89% encapsulation efficiency [175]). The CS-g-PCL chitosan derivatives also 
demonstrated improved stability and prolonged release [121]. Methyl ether PEG has 
been conjugated to a N-phthaloyl chitosan backbone forming PLC-g-mPEG [111]. 
When camptothecin was encapsulated inside the hydrophobic core of the self-
assemblies, the drug was shielded from hydrolysis. This shielding effect was reported 
to increase the half-life of camptothecin from 94 min to 76 h which is a vast increase. 
The longer the half-life of the drug, the greater therapeutic effect will occur over a 
sustained period of time [111]. These results are promising for the use of chitosan in 
chemotherapy, however in vivo studies must be carried out in order to determine the 
fate of the micellar carriers. 
 
To date, limited in vivo work has been published using amphiphilic polymers based 
on a preformed water soluble backbone attached with small hydrophobic pendant 
groups in anticancer therapeutics. Recently, we reported on the use of PAA modified 
with cholesterol  (5% molar ratio) known as Ch5-PAA [21] (Fig. 9C). This amphiphile 
was used to encapsulate the novel hydrophobic anticancer agent 
bisnaphthalamidoproyldiamino octane (BNIPDaoct) [62]. A Ch5-PAA, BNIPDaoct 
formulation (1 mgKg
-1
) was administered weekly to tumour bearing nude mice over a 
4 week period. Mice treated with the Ch5, BNIPDaoct formulation experienced a 
significant reduction in tumour growth (compared to the Ch5 control, tumour size: 
0.26 cm
3
) with the tumour volume on day 26 being only 0.1 cm
3
 (after 6,9,12,16 days, 
p values= 0.028,0.01, 0.003, 0.028 respectively) [62]. The decrease in tumour size 
was similar with the clinically used gemcitabine, tumour size 0.125 cm
3
 after the 26 
days. The results strongly suggested that when BNIPDaoct was formulated with Ch5 
possessed a similar antitumoral effect to the clinically used gemcitabine, making it an 
ideal candidate for anticancer therapeutics [62].  
 
Novel HPMA graft polymers conjugated with DOX have been reported to exhibit 
significantly increased blood circulation times of up to 96 h in mice bearing EL4T- 
cell lymphomal compared to their linear HPMA block copolymer counterparts [176]. 
A 6-fold and 50-fold increase in accumulation of drug in tumour sites was recorded 
compared to the linear counterpart and free drug. Polymer–DOX conjugates also 
exhibited a significantly higher antitumoral effect in vivo than the conjugated or the 
free DOX (in mice with 38C13 B-cell or EL4 T-cell lymphoma). A significant 
number of long-term-surviving (LTS) mice with EL4 T-cell lymphoma treated were 
recorded after only one dosage of 15 mg DOX equiv./kg on day 10. These results 
suggest that the novel HPMA graft polymer-drug conjugates hold great potential as 
clinical chemotherapy agents [176]. 
 
7.0 Comb Shaped Amphiphilic Polymers for Oral Delivery 
Similar to block copolymers, comb shaped amphiphilic polymers are mainly been 
studied for intravenous administration. However, recently a number of publications 
have emerged describing the use of comb shaped amphiphiles for oral administration 
of hydrophobic drugs such as griseofulvin, cyclosporine and camptothecin [25,92,177, 
62,178] while the use of polymeric micelles based on block copolymers for oral drug 
delivery have been extensively reviewed in recent years [148,179]. Oral delivery 
using polymeric self-assemblies is more complicated than intravenous delivery due to 
the complexity of the physiological and biological barriers imposed by the 
gastrointestinal tract (GIT). For example, the pH in the GIT varies greatly from empty 
stomach (pH1.2) to the small intestine (5-7) and colon (6-7.5) [148]. In addition, the 
presence of proteolytic enzymes, bile salts, food in the GIT fluid might also affect the 
use of these nano-carriers for oral delivery. Drug absorption usually occurs in small 
intestine consisting of an epithelial layer of enterocytes covered with mucus, which 
constitutes a formidable physical barrier to drug absorption. In oral drug delivery, it is 
imperative that the therapeutic agent is not prematurely released in the upper GIT 
before absorption occurs in small intestine. The polymeric self-assemblies must be 
stable and able to resist the dilution and the harsh environment in the GIT. 
 
Winnik and colleagues were one of the first groups examined the potential use of 
comb shaped amphiphilic polymers (hydrophobically modified dextran and 
hydroxypropylcellulose) for oral delivery [37,46,112,177]. Cyclosporine A (CsA) was 
incorporated into the micelles formed by these hydrophobically modified polymers 
with relatively low loading capacity of 1.7-8.5%w/w [3.7,46,112]. They showed the 
ability of these polymeric micelles in resisting dilution in simulated gastric and 
intestinal fluids, demonstrating their potential for oral delivery [112]. Further work to 
improve the absorption of these polymeric micelles was achieved via attachment of 
vitamin B12 residues to dextran-g-polyethyleneoxide cetyl ether (DEX-g-PEO-C16). 
The CsA loaded VitB12 modified polymeric micelles led to a significantly higher 
transport across Caco-2 cell monolayer compared to CsA in unmodified micelles 
[177]. Despite the potential demonstrated in the in vitro assessment, in vivo 
experiments are needed to confirm the potential of these systems. 
To date, there are limited in vivo studies on comb shaped amphiphilic 
polymers as oral delivery systems. Research led by Uchegbu and colleagues utilising 
cetylated polyethylenimine (PEI) has shown (Fig. 12) successful encapsulation of 
CsA with a 163-fold increase in aqueous solubility [8], which is significantly higher 
than hydrophobically modified polysaccharides designed by Winnik and colleagues 
[37] or block amphiphilic polymer methoxy poly(ethylene oxide)-b-poly(ɛ-
caprolactone) (PEO-b-PCL) [180]. Uchegbu and colleagues showed in vivo efficacy 
of this system where the blood plasma CsA levels were shown to be comparable to the 
commercially available Neoral
®
 formulation after oral administration to fasted rats 
[8]. These findings indicated that the PEI amphiphiles have promising potential as 
oral delivery vehicles [8]. 
 
We have also recently demonstrated the promising potential of PAA modified with 
aromatic structures such as Fmoc and Dansyl groups as well as cholesteryl (Ch) 
pendant groups in enhancing oral bioavailability of a poorly soluble drug, griseofulvin 
[61]. Apart from exhibiting superior drug loading efficiency (>100%), we were able 
to demonstrate that both Dansyl and Ch formulations showed significantly higher 
plasma drug level compared to griseofulvin in water when administered via oral 
gavage to rats. Using similar dose as the clinical dose (11.8mgkg
-1
), Ch formulation 
had significantly higher drug plasma concentrations at all time points compared to 
Dansyl formulation and the maximum plasma drug concentration was achieved at 4h. 
To date, few in vivo studies using block copolymers for improving bioavailability of 
griseofulvin have been carried out. Pierri and colleagues attempted to use 
Poly(lactide)-poly(ethylene glycol) micelles as oral carriers for griseofulvin [181]. 
However, this work did not proceed to in vivo study due to the extremely poor drug 
loading capacity (4% w/w). Kano and colleagues reported the use of poly[2-
methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate] (PMB) for 
enhancing the oral absorption of griseofulvin [182].  They found that PMB have 
similar Cmax/Dose ratios with formulations such as niosomes, liposomes, self-
emulsifying drug delivery systems and spray dried microparticles which range from 
0.02 to 0.19 [182]. Interestingly our result showed a much higher Cmax/Dose ratios of 
1.44 (Ch5) and 0.85 (Dansyl10) [61]. Although direct comparison is not applicable, 
however the high plasma drug concentrations achieved in both PAA formulations and 
the differences observed between these formulations perhaps indicate there are other 
contributing factors at play apart from solubilisation mechanism. More work needs to 
be done to understand the interaction of these self- assemblies with the gut enterocytes 
and subsequent absorption, the influence of bile salt, food, stomach acidity and other 
physiological factors when using these novel solubilisers for oral delivery.  
 
8.0 Other applications for comb shaped amphiphilic polymers 
Comb shaped amphiphilic polymers have also been developed as protein 
complexation agents, with the potential to facilitate oral delivery of proteins such as 
insulin whilst protecting them from enzymatic degradation throughout their journey 
[70]. One of the pioneering groups which utilises hydrophobically modified 
polyelectrolytes for oral protein delivery is Cheng and colleagues. They synthesised a 
range of poly(allylamine) amphiphiles with cetyl (Ce), cholesterol (Ch), and 
quaternary ammonium moieties (Q) grafted onto the backbone [70,76,92]. They 
systematically studied the effect of polymer architecture, mainly the type of 
hydrophobic pendant groups on complexation efficiency and degradation inhibition 
for oral insulin delivery. PAA amphiphiles were capable of forming a complex with 
insulin via hydrophobic and electrostatic interactions and the complexation efficiency 
is dependant on the type of hydrophobic pendant groups or the presence of quaternary 
ammonium moieties [70, 92]. Equally, polymer architecture also played a key role in 
the protection against enzymatic degradation in vitro. The level of protection against 
insulin degradation in the presence of proteases (tyrpsin, α-chymotrypsin and pepsin) 
is dependant on the type of enzymes, the presence of quaternary ammonium moieties 
and the type of the hydrophobic pendant groups.  They concluded that in order to 
obtain effective protection from all these enzymes, it may be necessary to combine a 
number of the PAA amphiphiles as the cholesterol, cetyl, palmitoyl and quaternary 
ammonium groups each possessed their own unique enzymatic protection profile [70]. 
 
Subsequent work by Cheng and colleagues looked at the complexation of quaternised 
palmitoyl poly(allylamine) (QPa) with salmon calcitonin (sCT) [33]. Calcitonin is a 
32-residue calcium regulating peptide hormone produced by parafollicular cells in the 
thyroid, which has been used clinically as an adjunct treatment for osteoporosis and 
also as a second line treatment for Paget disease. Complexation generally takes place 
between oppositely charged polyelectrolyte and protein. However, in this work, 
Cheng and colleagues demonstrated that complexation can also occur between 
hydrophobically modified positively charged PAA with positively charged sCT at 
physiological pH [33]. When compared to free sCT, the complexes showed increased 
resistance to peptidases and serum and liver homogenates. Additionally, sCT 
complexed with QPa showed significant stability when stored at room temperature 
compared to free sCT.  After IV administration on fasted Wistar rats (40 µgmL
-1
), the 
complexes showed reduced serum concentrations after 120 minutes, demonstrating 
the bioactivity of complexed sCT was retained. Free and complexed sCT but not QPa 
also reduced serum calcium over 240 min following intra-jejunal administration. 
Cheng concluded that these nanocomplexes are stable, bioactive and resistant to a 
range of peptidases [33]. These enhanced features suggest that they may have the 
potential for improved efficacy when formulated for injected and oral delivery.  
 
9.0 Future Prospects of comb shaped amphiphilic polymers 
To date there has been no commercial success for comb shaped amphiphilic polymers 
while there are six polymeric micelles based on amphiphilic block copolymers in 
various phases of clinical trials for chemotherapy [183]. However, with the recent 
plethora of literature on the use of comb shaped amphiphilic polymers for 
hydrophobic drug and protein delivery suggests that it is only a matter of time for 
comb shaped polymers to follow in the success of amphiphilic block copolymers 
amphiphiles. To date, numerous patents have been filed through both the intellectual 
property organization and the worldwide intellectual property organization for the use 
of a multitude of graft or comb shaped polymers for drug, gene and protein delivery 
vehicles [184,185]. However, boundaries such as the cross-over from synthetic 
organic chemistry to molecular cell biology and pharmacokinetic analysis coupled 
with industrial insight still to be fully exploited before the use of comb shaped 
amphiphilic polymers in clinics can be realised. Bearing this in mind, as we move 
forward, increased knowledge, understanding and expertise expand and so too does 
potential for success.  
 
Executive Summary 
 Polymer architecture such as type and level of hydrophobic pendant groups, 
the molecular weight and the type of polymer backbone, the presence of 
hydrophilic moieties have direct impact on physicochemical properties of self-
assemblies. 
 Drug loading is affected by a number of factors including the type and level of 
hydrophobic pendant groups, the structural compatibility of the hydrophobic 
pendant with the encapsulated drug and physicochemical properties of drug. 
 Comb shaped amphiphilic polymers have been reported to solubilise a range 
of hydrophobic drugs such as doxorubicin, paclitaxcel, camptothecin and 
griseofulvin and stimuli response comb shaped polymers are now being 
explored. 
 Oral delivery using hydrophobically modified polymers show promising 
potential for hydrophobic drug and proteins and peptides. 
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glycol (PAA-g-PEG)[175]. 
Figure 12. Poly(ethylenimine) modified with cetyl chains and quaternary ammonium 
pendant groups for CsA solubilisation [5]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 1.  
Polymer 
Backbone 
Hydrophobic 
pendant groups 
Hydrophilic 
moieties 
Encapsulated drugs 
Chitosan Palmitoyl [105,54]. 
cetyl [106], 
poly(caprolactone) 
[107], 
aminoacid[108] 
Quaternary 
ammonium 
moieties [109] 
PEG [110] 
All-trans retinoic acid 
[110], 
doxorubicin [108], 
camptothecin [111], 
prednisolone [109], 
propofol [109], 
Ketoprofen [38] 
 
Dextran cetyl [112], 
poly(caprolactone) 
[47] 
 
Spermine 
[113], 
Quaternary 
ammonium 
[113], 
 
Paclitaxel [47], 
Cyclosporin A [112], 
Pullulan Cholesterol [114], 
Acetyl [114] 
 Clonazepam [115] 
Doxorubicin [116] 
Methyl cellulose Cetyl [37] 
Octadecyl [37] 
 Cyclosporin A [37] 
Poly(allylamine) Cetyl [17], palmitoyl 
[17], cholestryl 
[17,21], aromatic 
[21] 
Quaternary 
ammonium 
[17] 
Propofol [61] 
Prednisolone [61] 
Griseofulvin [61] 
Gemcitabine [62] 
Poly(ethylenimine) Cetyl [8,69], 
Palmitoyl [58], 
Cholesterol [52], 
Poly(caprolactone) 
[60], 
Polyglycerol [117] 
 
Quaternary 
ammonium 
[58], 
PEG [58] 
Cyclosporin A[8], 
doxorubicin [60], 
Poly(L-lysine) Palmitoyl [28,118] 
Poly(L-Histine) 
[119] 
PEG [28,118]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  
Amphiphilic polymer Polymer Architecture CAC value mgmL
-1 
 
Poly(ethylenimine)-g-
cetyl1.8 (C1.8) [8] 
Comb shaped 0.01000 
Poly(allylamine)-g-
cholesterol5 (Ch5) [17] 
Comb shaped 0.02000 
Poly(aspargine)-g-poly 
(capro-lactone)6 (PAsn-g-
PCL6) [120] 
Comb Shaped 0.00250 
Chitosan-g-
poly(caprolactone)24 (CS-g-
PCL24) [121] 
Comb Shaped 0.00890 
Poly(D-L-lactide-co-
glycolide) (PEI-PLGA) 
[122] 
Block 0.00154 
Poly(2-ethyl-2-oxazoline)-
block-poly(ε-caprolactone) 
(PEtoz-PCLs) [123] 
Block 0.0018 
Poly(ethylene oxide)-block- 
poly (hydroxyethyl L-
aspartamide) (PEO-b-
PHAA22) [124] 
Block  0.0090 
Poly(vinylpyrrolidone)-b-
poly(D,L-lactine)-b-
poly(vinyl pyrrolidone) 
(PVP-b-PDLLA-b-PVP) 
[93] 
Triblock  0.00510 
Poly(ethylene oxide)-b-poly 
(metha crylate)-b-poly(L-
lysine) PEO-b-PMA-PLS 
[125] 
Triblock 0.01000 
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Dilution above CAC 
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hydrophobic drug 
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responsive 
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Hydrophobic 
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